BioSpace News Archive

Biosion, Inc., a global, clinical stage biotechnology company, announced that Biosion and OBI Pharma Inc. have signed an exclusive license agreement under which OBI Pharma will be granted a global exclusive license to Biosion’s proprietary anti-Trop2 humanized monoclonal antibody, BSI04702, for developing next generation biologics.

Mallinckrodt plc today announced results of a retrospective, observational medical chart review study assessing real world treatment outcomes among cutaneous T-cell lymphoma (CTCL) patients who initiated therapy with extracorporeal photopheresis (ECP).

Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer.

Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, will provide a clinical update on CLN-081 during a webinar on Thursday, December 16, 2021, at 8:00 a.m. ET.

Trevena, Inc. (Nasdaq: TRVN), today announced it is advancing TRV045 into clinical development, following receipt of a notification from the U.S. Food and Drug Administration (FDA) that the study may proceed.

CareDx, Inc. today announced a partnership with the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) organization to use their patient registry to evaluate the long-term impact of using AlloSure ® Kidney, for routine organ transplant surveillance in pediatric kidney patients.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that it has entered into a research collaboration with Columbia University focused on advancing recombinant trefoil factor family 2 -based therapeutic candidates in the treatment of gastric and colorectal cancers.

Autolus Therapeutics plc presented further progress on obecabtagene autoleucel (obe-cel) in an oral presentation [Abstract 477] entitled “Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process” at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publication of Phase 3 clinical data in Muscle and Nerve.